Plant Health Care PLC
16 April 2007
Plant Health Care plc
('Plant Health Care' or 'the Company')
Successful trial results for Plant Health Care's unique technology
- Harpin-based N-Hibit product successfully suppresses nematodes
in soybeans and increases yields in cotton by up to 15%
Plant Health Care (AIM: PHC.L), a leading provider of natural products for
plants and soil, is pleased to report the success of independent trials of its
Harpin-based N-Hibit seed treatments on cotton and soybean crops. This takes the
Company a further step toward commercialisation of this product in these and
other crops.
The trials, undertaken by Southern Illinois University, demonstrated that
N-Hibit reduced cyst nematodes in soybean roots by up to 60%, resulting in
average increases in yield of 8%. Approximately 150 million acres of soybeans
are planted each year in the US and Brazil alone. Similarly, when used in
combination with other treatments offered by the major agrichemical businesses,
the trials showed N-Hibit increased the yield of cotton by up to 15%.
Harpin is a fundamentally new and patented technology based on naturally
occurring proteins which activate internal plant growth and stress-defence
responses. Plant Health Care acquired the Harpin technology as a part of its
acquisition of the majority of the assets and business of Eden BioScience in
February this year (2007).
Plant Heath Care also announced today that it is in discussions with the world's
largest crop science companies regarding supply agreements for its Harpin
technology, and, further to its earlier agreement with Bayer CropScience, for
other uses of Myconate, its mycorrhizal stimulant.
John Brady, Chief Executive of Plant Health Care, commented: 'N-Hibit is the
only product currently available, natural or otherwise, which can suppress
nematodes economically in soybean crops.
'Overall these trial results fully endorse our expectations the Harpin
technology will be as important to Plant Health Care as Myconate.'
For further information:
Plant Heath Care plc Tavistock Communications
John Brady, Chief Executive Jeremy Carey/Simon Compton
16 -17 April Tel: 020 7920 3150 Tel: 020 7920 3150
Thereafter: 001 603 525 3702
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.